Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

CGP 62221

Known as: CGP62221 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Introduction Allogeneic stem cell transplant (alloSCT) provides pts with FLT3-ITD+ AML the highest likelihood of sustained… Expand
2018
2018
Midostaurin (PKC412) is being investigated for the treatment of acute myeloid leukemia (AML) and advanced systemic mastocytosis… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2017
2017
The absorption, metabolism, and excretion of midostaurin, a potent class III tyrosine protein kinase inhibitor for acute… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2016
2016
Proteomic-based drug testing is an emerging approach to establish the clinical value and anti-neoplastic potential of multikinase… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2013
Highly Cited
2013
AbstractPurpose Midostaurin (PKC412), a multitargeted tyrosine kinase inhibitor that targets FMS-related tyrosine kinase 3 and… Expand
  • table 1
  • figure 1
  • figure 2
  • table 3
  • figure 3
2012
2012
Abstract 4913 Background: Among tyrosine kinase inhibitors, midostaurin (PKC412) takes place in the treatment of patients… Expand
Review
2009
Review
2009
e14540 Background: Midostaurin is a multi-tyrosine-kinases inhibitor targeting class III tyrosine-protein-kinases, including Fms… Expand
2008
2008
Midostaurin is a novel potent inhibitor of both protein kinase C and the major receptor for vascular endothelial growth factor… Expand
2008
2008
AbstractBackground and objective: Midostaurin, a novel potent inhibitor of protein kinase C enzyme and class III receptor… Expand